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Identity 
Other names: 4F9; C33; GR15; IA4; KAI1; R2; 
SAR2; ST6; TSPAN27; Tetraspanin-27; Tspan-27 









We do notice that, in literature, there is one more 
splicing variant with functional importance (Lee et al., 
2003). In this variant, the 84 bp exon that encodes the 
amino acids 215-242 of CD82/kAI1 protein is 
selectively deleted. However, the chromosome location 
and exon numbers of this splicing variant described in 
the publication are not consistent with those for the 
other two splicing variants herein. There is no gene 
accession number be assigned to this slicing variant. 
Thus, this variant is not presented in the following 
diagram. 
Description 
Gene type: protein coding.  
Gene size: 54.2 kb.  
Two splicing variants in addition to wild type 
(NM_002231 or CD82 wild type consists of 10 exons; 
NM_001024844 or the splicing variant lacking exon 6 




NM_002231 encodes the longer isoform, i.e., CD82 wild type; NM_001024844 encodes a shorter isoform, which lacks exon 6. 
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CD82 is a 4-transmembrane glycoprotein and belongs to the tetraspanin superfamily. This family of proteins is characterized by the 
conservation of several motifs located within the extracellular and transmembrane domains. CD82 undergoes two types of post-




Transcript length: NM_002231 is 1715 bp; 
NM_001024844 is 1640 bp; and the splicing variant 
likely lacking exon 8 is 1631 bp. 
Protein 
Description 
Size: 267 amino acids.  
Because of the glycosylation, the molecular weight of 
CD82 proteins ranges between 30-90 kDa depending 
on tissue and cell types. 
Expression 
CD82 is ubiquitously expressed in various human 
tissues such as epithelium and endothelium. CD82 
expression is frequently diminished or lost in invasive 
and metastatic solid-tumor tissues. 
Localisation 
CD82 is found in the plasma membrane, endosomes, 
lysosomes, and exosomes. 
Function 
In relation to cancer, CD82 function is to inhibit tumor 
invasion and suppresses tumor metastasis.  
Palmitoylation is essential for CD82 function as well as 
the presence of three polar residues, NQE, located 
within its transmembrane domains. CD82 associates 
with other transmembrane proteins such as 
tetraspanins, integrins, Ig superfamily members, and 
growth factor receptors and intracellular signaling 
proteins to regulate membrane microdomain 
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organization, vesicular trafficking, and transmembrane 
signaling. 
Homology 
Mouse and other human tetraspanins. 
Mutations 
Note 
Currently there is no report for the disease-related or 
biologically significant mutation for CD82 gene (See 
HGMD). 
Implicated in 
Prostate cancer, breast cancer, 
pancreatic cancer, gastric cancer, 
bladder cancer, ovarian cancers, non-
small-cell lung carcinoma, 
hepatocellular carcinoma, oral 
squamous cell carcinoma, and other 
solid tumors 
Note 
Invasion and metastasis suppression.  
CD82 is expressed in many normal tissues such as 
epithelia. In invasive or metastatic cancers, CD82 
expression is typically reduced or lost. In most of the 
solid tumors studied so far, CD82 expression is 
inversely correlated with the invasive and metastatic 
abilities of malignant tumors. 
The metastasis-suppressive effect of CD82 can be 
observed in the animal studies of cancer metastasis by 
re-introducing CD82 expression in various metastatic 
cancer cell lines such as prostate cancer AT6.1, prostate 
cancer LNCaP, fibroblastoma HT1080, melanoma 
MDA-MB-435, breast cancer LCC6, liver cancer 
MHCC97-H, and lung cancer LLC lines. 
The observations of CD82-mediated suppression of 
cancer metastasis in animal models are supported by a 
variety of clinical studies on the human cancers from 
prostate, breast, ovary, colon, lung, stomach, liver, and 
other organs. 
CD82 attenuates the signaling from integrins and 
growth factor receptors such as epidermal growth 
factor receptor and c-Met. CD82 also reorganizes the 
membrane micordomains including tetraspanin webs 
and lipid rafts. The interaction of CD82 and its counter-
receptor DARC inhibits tumor cell proliferation and 
induces senescence. 
Prognosis 
The lower or no expression of CD82 in the tumors from 
prostate, breast, colon, stomach, bladder, lung, liver, 
pancreas, ovary, and other organs predicts the poor 
clinical outcome. Conversely, the expression of CD82 
wild type proteins in solid tumors reflects the less 
invasiveness and low metastatic potential of the tumors. 
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